JP2023551559A5 - - Google Patents
Info
- Publication number
- JP2023551559A5 JP2023551559A5 JP2023533838A JP2023533838A JP2023551559A5 JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5 JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023533838 A JP2023533838 A JP 2023533838A JP 2023551559 A5 JP2023551559 A5 JP 2023551559A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- aforementioned
- antibody
- day cycle
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20211862 | 2020-12-04 | ||
| EP20211862.6 | 2020-12-04 | ||
| EP21158806 | 2021-02-23 | ||
| EP21158806.6 | 2021-02-23 | ||
| EP21163696.4 | 2021-03-19 | ||
| EP21163696 | 2021-03-19 | ||
| EP21172671 | 2021-05-07 | ||
| EP21172671.6 | 2021-05-07 | ||
| EP21177336.1 | 2021-06-02 | ||
| EP21177336 | 2021-06-02 | ||
| EP21205447 | 2021-10-29 | ||
| EP21205447.2 | 2021-10-29 | ||
| PCT/EP2021/084133 WO2022117799A2 (en) | 2020-12-04 | 2021-12-03 | Anti-cd19 combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551559A JP2023551559A (ja) | 2023-12-08 |
| JP2023551559A5 true JP2023551559A5 (https=) | 2024-12-11 |
Family
ID=78821967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533838A Pending JP2023551559A (ja) | 2020-12-04 | 2021-12-03 | 抗ｃｄ１９併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184208A1 (https=) |
| EP (1) | EP4255480A2 (https=) |
| JP (1) | JP2023551559A (https=) |
| KR (1) | KR20230131464A (https=) |
| AU (1) | AU2021391623A1 (https=) |
| BR (1) | BR112023010885A2 (https=) |
| CA (1) | CA3204063A1 (https=) |
| CL (1) | CL2023001581A1 (https=) |
| IL (1) | IL303384A (https=) |
| MX (1) | MX2023006538A (https=) |
| TW (1) | TW202237184A (https=) |
| WO (1) | WO2022117799A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| CA3255552A1 (en) * | 2021-12-22 | 2023-06-29 | Incyte Corporation | TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY |
| AU2023285109A1 (en) * | 2022-06-10 | 2024-12-12 | Incyte Corporation | Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer |
| KR102835682B1 (ko) * | 2022-06-16 | 2025-07-22 | 애브비 바이오테라퓨틱스 인크. | 항-cd19 항체-약물 접합체 |
| WO2024037594A1 (en) * | 2022-08-19 | 2024-02-22 | Beijing Innocare Pharma Tech Co., Ltd. | Combination treatment with orelabrutinib and tafasitamab |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| FI3916392T3 (fi) * | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
| US20200230254A1 (en) * | 2016-07-22 | 2020-07-23 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and rchp |
| CN118593691A (zh) * | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
-
2021
- 2021-12-03 WO PCT/EP2021/084133 patent/WO2022117799A2/en not_active Ceased
- 2021-12-03 IL IL303384A patent/IL303384A/en unknown
- 2021-12-03 US US17/541,627 patent/US20220184208A1/en active Pending
- 2021-12-03 BR BR112023010885A patent/BR112023010885A2/pt unknown
- 2021-12-03 AU AU2021391623A patent/AU2021391623A1/en active Pending
- 2021-12-03 TW TW110145312A patent/TW202237184A/zh unknown
- 2021-12-03 CA CA3204063A patent/CA3204063A1/en active Pending
- 2021-12-03 EP EP21819888.5A patent/EP4255480A2/en active Pending
- 2021-12-03 JP JP2023533838A patent/JP2023551559A/ja active Pending
- 2021-12-03 KR KR1020237022358A patent/KR20230131464A/ko active Pending
- 2021-12-03 MX MX2023006538A patent/MX2023006538A/es unknown
-
2023
- 2023-06-01 CL CL2023001581A patent/CL2023001581A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023551559A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2022531408A5 (https=) | ||
| JP2020515577A5 (https=) | ||
| KR20240151809A (ko) | Fcrn 길항제를 사용하여 근염을 치료하는 방법 | |
| JP2022541591A5 (https=) | ||
| TW202346342A (zh) | 抗tim-3抗體與抗pd-1抗體的藥物組合 | |
| IL324054A (en) | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa | |
| JP2024521105A5 (https=) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2024540435A5 (https=) | ||
| JP2023546504A5 (https=) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP2023506779A5 (https=) | ||
| JP2022549218A5 (https=) | ||
| JP2022547061A5 (https=) | ||
| JP2023551519A5 (https=) | ||
| JP2022521773A5 (https=) | ||
| JP2025526402A5 (https=) | ||
| JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| JP2023550311A5 (https=) | ||
| CA3117142C (en) | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa | |
| CA3215919A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| IL311796A (en) | Anti-galectin-9 antibodies and their therapeutic uses |